

## COUNTRY GENERAL INFORMATION

Total population:	31 407 298
Gender F/M (%):	42.9 / 57.1
Population, age group <15 / ≥ 15 years (%):	26 / 75
Life expectancy at birth (F/M, years):	76 / 73
GDP (PPP int \$):	54 160
Income status:	High income
Number of 1 <sup>st</sup> sub-national administrative level divisions, name:	20, Region



## EPIDEMIOLOGY

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	4	248	1 089	0
Number of relapses: <sup>1</sup>	No data	No data	No data	N/A
<b>Total number of cases:</b>	<b>4</b>	<b>248</b>	<b>1 089</b>	<b>0</b>
Imported cases (#, %):	No data	No data	No data	No data
Gender distribution (% F):	75	No data	No data	N/A
Age group distribution (% , <5 / 5-14 / >14):	25 / 75 / 0	No data	No data	N/A
Incidence rate (cases/10 000 population in endemic areas):	0.02	0.67	0.45	N/A
Number of endemic 1 <sup>st</sup> sub-national administrative level divisions:	1	3	12	N/A
Population at risk (% , # at risk / total population): <sup>2</sup>	5% 1 621 967/ 31 407 298	12% 3 687 320/ 31 407 298	77% 24 231 883/ 31 407 298	N/A
Was there any outbreak?	No	No data	No data	N/A
Number of new foci: <sup>3</sup>	0	No data	No data	N/A



## Monthly distribution of new cases (January-December)

2016	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	0	0	1	2	0	1	0	0	0	0	0	0
ACL	30	47	23	18	18	8	11	26	8	14	27	18
ZCL	142	140	107	90	84	54	97	100	61	67	63	84

N/A not applicable; VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis



## Number of new cases and Incidence rate/10 000 at the national level from 2001 to 2016




<sup>1</sup> Defined as: "A patient who discharged with initial cure and returned with clinical signs of VL and positive parasitology" for VL and "Recurrence of clinical signs after complete cure" for CL

<sup>2</sup> Defined as: "Number of people living in 1st sub-national administrative level endemic areas"

<sup>3</sup> Defined as: "In this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever"

## Disease distribution of new VL, ACL and ZCL cases at Regional level per 10 000 population (2016)



### CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1978
Type of surveillance (CL / VL):	Integrated / Integrated
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	Deltamethrin, Lambda-cyhalothrin, Etofenoprox
Year latest national guidelines (CL / VL):	undefined / No data
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	No / Yes
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities (CL / VL):	No data / No data

### DIAGNOSIS

	VL	ACL	ZCL	MCL
Number of people screened actively for:	No data	No data	No data	N/A
Number of people screened passively for:	No data	No data	No data	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / total cases):	No data	No data	No data	N/A
Proportion of positive slides (% , # slides + / total slides):	No data	No data	No data	N/A
Cases diagnosed clinically (% , # clinical cases / total cases):	No data	N/A	N/A	N/A
Percentage of cases with HIV-VL coinfection:	0% (0/4)	N/A	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

### TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): Yes / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Liposomal amphotericin B, Sodium stibogluconate (SSG)

### INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	ACL	ZCL
Cases that completed treatment (% , # completed treatment / new cases):	No data	No data	No data
Initial cure rate (% , # cases initially cured / new cases):	100% (4/4)	No data	No data
Failure rate (% , # cases with treatment failure / new cases): <sup>4</sup>	0% (0/4)	No data	No data
Case fatality rate (% , # cases who died / new cases):	0% (0/4)	No data	No data

VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL = zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis

<sup>4</sup>Defined as "failure of improvement or deterioration during the treatment course" for VL and "Deterioration of clinical signs within the first 2 weeks, or absence of improvement after completion of treatment" for CL